Sugi Predict

Sugi Predict / Compounds / Cefamandole

Cefamandole

Cefamandole

SCHEMBL146171

Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](O)c3ccccc3)[C@H]2SC1.[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Cefamandole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC22A6 Q4U2R8 2/20 0.98
▸ SLC22A8 Q8TCC7 2/20 0.98
▸ SLC22A11 Q9NSA0 2/20 0.98
▸ NR1I2 O75469 2/20 0.98
▸ PGR P06401 2/20 0.98
▸ PPARG P37231 1/20 0.98
▸ MAPT P10636 10/20 0.86
▸ TDP1 Q9NUW8 10/20 0.86
▸ POLB P06746 10/20 0.86
▸ ALDH1A1 P00352 5/20 0.86
▸ HSD17B10 Q99714 5/20 0.86
▸ KDM4E B2RXH2 2/20 0.86
▸ CYP3A4 P08684 1/20 0.86
▸ HPGD P15428 1/20 0.86
▸ APEX1 P27695 1/20 0.86
▸ PTPN7 P35236 1/20 0.86
▸ SLC6A4 P31645 1/20 0.76
▸ CTDSP1 Q9GZU7 2/20 0.71
▸ HTT P42858 1/20 0.67
▸ PDE3A Q14432 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefamandole SCHEMBL29033085 1.00 SLC22A6 (0.98) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL11668899 0.99 SLC22A6 (0.97) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL37287 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL10478386 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL10604265 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL10478382 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL14509205 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL16072810 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL17131900 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR
Cefamandole SCHEMBL11883501 0.99 SLC22A6 (1.00) SLC22A6SLC22A8SLC22A11NR1I2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 — — US claimed
CN-111526873-B For modulating microbial colonization substituted diphenylacetylenes of (2) 生物曼迪克斯有限责任公司 2025-03-04 — — CN claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 — — US claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 — — US claimed
CN-115372523-A Method for detecting sodium azide in medicine or intermediate thereof 山东建筑大学 2022-11-22 — — CN claimed
CN-112694488-B Synthesis method of L-type cefamandole nafate 苏州盛达药业有限公司 2022-04-22 — — CN claimed
CN-113559264-A Methods of treating microbial infections including mastitis 罗达制药公司 2021-10-29 — — CN claimed
CN-113144197-A Method of treating topical microbial infections 罗达制药公司 2021-07-23 — — CN claimed
CN-112912386-A Cell penetrating peptide based on influenza virus M2 protein 中国医学科学院基础医学研究所 2021-06-04 — — CN claimed
CN-112312919-A Composition comprising beta-glucan-peptide complex and antibiotic for preventing, ameliorating or treating inflammatory disease 株式会社贵真生物技术 2021-02-02 — — CN claimed
US-20040131628-A1 Nucleic acids for the treatment of disorders associated with microorganisms BRATZLER ROBERT L (US) 2004-07-08 — — US claimed
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds POINT THERAPEUTICS, INC. 2004-04-22 — — US claimed
WO-2004004658-A2 METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS POINT THERAPEUTICS, INC. (US) 2004-01-15 — — WO claimed
US-6245735-B1 CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2001-06-12 — — US claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 — — US claimed
EP-0007689-B1 PRODUCTION OF SODIUM CEPHAMANDOLE DERIVATIVES ELI LILLY AND COMPANY (US) 1982-08-04 — — EP claimed
EP-0007689-A1 Production of sodium cephamandole derivatives ELI LILLY AND COMPANY (US) 1980-02-06 — — EP claimed
US-4168376-A HYDROLYSIS OF O-FORMYL ESTER IN METHANOL ELI LILLY AND COMPANY (US) 1979-09-18 — — US claimed
US-3947415-A Cefamandole derivatives ELI LILLY AND COMPANY (US) 1976-03-30 — — US claimed
US-3947414-A Cefamandole derivatives ELI LILLY AND COMPANY (US) 1976-03-30 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds BCAT1, BCAT2, APOB SLC22A6 1093/4885SLC22A8 360/4885SLC22A11 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.